6,765 research outputs found
The agrin gene codes for a family of basal lamina proteins that differ in function and distribution
We isolated two cDNAs that encode isoforms of agrin, the basal lamina protein that mediates the motor neuron-induced aggregation of acetylcholine receptors on muscle fibers at the neuromuscular junction. Both proteins are the result of alternative splicing of the product of the agrin gene, but, unlike agrin, they are inactive in standard acetylcholine receptor aggregation assays. They lack one (agrin-related protein 1) or two (agrin-related protein 2) regions in agrin that are required for its activity. Expression studies provide evidence that both proteins are present in the nervous system and muscle and that, in muscle, myofibers and Schwann cells synthesize the agrin-related proteins while the axon terminals of motor neurons are the sole source of agrin
cDNA that encodes active agrin
Agrin is thought to mediate the motor neuron-induced aggregation of AChRs and AChE on the surface of muscle fibers at neuromuscular junctions. We have isolated a cDNA from a chick brain library that, based on sequence homology and expression experiments, codes for active agrin. Examination of the sequence reveals considerable similarity to homologous cDNAs previously isolated from ray and rat libraries. A conspicuous difference is an insertion of 33 by in chick agrin cDNA, which endows the encoded protein with AChR/AChE aggregating activity. Homologous transcripts having the 33 by insertion were detected in the ray CNS, which indicates that an insertion of similar size is conserved in agrin in many, if not all, vertebrate species. Results of in situ hybridization studies and PCR experiments on mRNA isolated from motor neuron-enriched fractions of the spinal cord indicate that, consistent with the agrin hypothesis, motor neurons contain transcripts that code for active agrin
Agrin isoforms and their role in synaptogenesis
Agrin is thought to mediate the motor neuron-induced aggregation of synaptic proteins on the surface of muscle fibers at neuromuscular junctions. Recent experiments provide direct evidence in support of this hypothesis, reveal the nature of agrin immunoreactivity at sites other than neuromuscular junctions, and have resulted in findings that are consistent with the possibility that agrin plays a role in synaptogenesis throughout the nervous system
Artificial restoration of the linkage between laminin and dystroglycan ameliorates the disease progression of MDC1A muscular dystrophy at all stages
Laminin-α2 deficient congenital muscular dystrophy, classified as MDC1A, is a severe
progressive muscle-wasting disease that leads to death in early childhood. MDC1A is caused by
mutations in lama2, the gene encoding the laminin-α2 chain being part of laminin-2, the main
laminin isoform present in the extracellular matrix of muscles and peripheral nerves. Via selfpolymerization,
laminin-2 forms the primary laminin scaffold and binds with high affinity to α-
dystroglycan on the cell surface, providing a connection to the cytoskeleton via the
transmembranous protein β-dystroglycan. Deficiency in laminin-α2 leads to absence of laminin-2
and to upregulation of laminin-8, a laminin isoform that cannot self-polymerize and does not bind
to α-dystroglycan. Therefore, in laminin α2-deficient muscle the chain of proteins linking the
intracellular contractile apparatus via the plasma membrane to the extracellular matrix is
interrupted. Consequently, muscle fibers loose their stability and degenerate what finally leads to
a progressive muscle wasting.
In previous studies, we have shown that a miniaturized form of the extracellular matrix protein
agrin, which is not related to the disease-causing lama2 gene and was designed to contain highaffinity
binding sites for the laminins and for α-dystroglycan, was sufficient to markedly improve
muscle function and overall health in the dyW-/- mouse model of MDC1A. In a follow-up study we
provided additional evidence that mini-agrin, both increases the tolerance to mechanical load but
also improves the regeneration capacity of the dystrophic muscle.
We now report on our progress towards further testing the use of this approach for the treatment
of MDC1A. To test whether mini-agrin application after onset of the disease would still ameliorate
the dystrophic symptoms, we have established the inducible tetracycline-regulated “tet-off”
expression system in dyW-/- mice to temporally control mini-agrin expression in skeletal muscles.
We show that mini-agrin slows down the progression of the dystrophy when applied at birth or in
advanced stages of the disease. However, the extent of the amelioration depends on the
dystrophic condition of the muscle at the time of mini-agrin application. Thus, the earlier miniagrin
is applied, the higher is the profit of its beneficial properties.
In addition to gene therapeutical approaches, the increase of endogenous agrin expression levels
in skeletal muscles by pharmacologically active compounds would be a safe and promising
strategy for the treatment of MDC1A. To evaluate the potential and pave the way to further
expand on the development of such a treatment, we determined whether full-length agrin
ameliorates the dystrophic phenotype to a comparable extent as it was observed by application of
mini-agrin. We provide evidence that constitutive overexpression of chick full-length agrin in dyW-/-
muscle ameliorates the dystrophic phenotype, although not as pronounced as mini-agrin does.
In conclusion, our results are conceptual proof that linkage of laminin to the muscle fiber
membrane is a means to treat MDC1A at any stage of the disease. Our findings definitely
encourage to further expanding on this therapeutic concept, especially in combination with
treatment using functionally different approaches. Moreover, these experiments set the basis for
further developing clinically feasible and relevant application methods such as gene therapy4
and/or the screening of small molecules able to upregulate production of agrin in muscle
Recommended from our members
Agrin-induced acetylcholine receptor clustering in mammalian muscle requires tyrosine phosphorylation.
Agrin is thought to be the nerve-derived factor that initiates acetylcholine receptor (AChR) clustering at the developing neuromuscularjunction. We have investigated the signaling pathway in mouse C2 myotubes and report that agrin induces a rapid but transient tyrosine phosphorylation of the AChR beta subunit. As the beta-subunit tyrosine phosphorylation occurs before the formation of AChR clusters, it may serve as a precursor step in the clustering mechanism. Consistent with this, we observed that tyrosine phosphorylation of the beta subunit correlated precisely with the presence or absence of clustering under several experimental conditions. Moreover, two tyrosine kinase inhibitors, herbimycin and staurosporine, that blocked beta-subunit phosphorylation also blocked agrin-induced clustering. Surprisingly, the inhibitors also dispersed preformed AChR clusters, suggesting that the tyrosine phosphorylation of other proteins may be required for the maintenance of receptor clusters. These findings indicate that in mammalian muscle, agrin-induced AChR clustering occurs through a mechanism that requires tyrosine phosphorylation and may involve tyrosine phosphorylation of the AChR itself
Effects of Purified Recombinant Neural and Muscle Agrin on Skeletal Muscle Fibers in Vivo
Aggregation of acetylcholine receptors (AChRs) in muscle fibers by nerve-derived agrin plays a key role in the formation of neuromuscular junctions. So far, the effects of agrin on muscle fibers have been studied in culture systems, transgenic animals, and in animals injected with agrin–cDNA constructs. We have applied purified recombinant chick neural and muscle agrin to rat soleus muscle in vivo and obtained the following results. Both neural and muscle agrin bind uniformly to the surface of innervated and denervated muscle fibers along their entire length. Neural agrin causes a dose-dependent appearance of AChR aggregates, which persist ≥7 wk after a single application. Muscle agrin does not cluster AChRs and at 10 times the concentration of neural agrin does not reduce binding or AChR-aggregating activity of neural agrin. Electrical muscle activity affects the stability of agrin binding and the number, size, and spatial distribution of the neural agrin–induced AChR aggregates. Injected agrin is recovered from the muscles together with laminin and both proteins coimmunoprecipitate, indicating that agrin binds to laminin in vivo. Thus, the present approach provides a novel, simple, and efficient method for studying the effects of agrin on muscle under controlled conditions in vivo
The COOH-terminal domain of agrin signals via a synaptic receptor in central nervous system neurons
Agrin is a motor neuron–derived factor that directs formation of the postsynaptic apparatus of the neuromuscular junction. Agrin is also expressed in the brain, raising the possibility that it might serve a related function at neuron–neuron synapses. Previously, we identified an agrin signaling pathway in central nervous system (CNS) neurons, establishing the existence of a neural receptor that mediates responses to agrin. As a step toward identifying this agrin receptor, we have characterized the minimal domains in agrin that bind and activate it. Structures required for agrin signaling in CNS neurons are contained within a 20-kD COOH-terminal fragment of the protein. Agrin signaling is independent of alternative splicing at the z site, but requires sequences that flank it because their deletion results in a 15-kD fragment that acts as an agrin antagonist. Thus, distinct regions within agrin are responsible for receptor binding and activation. Using the minimal agrin fragments as affinity probes, we also studied the expression of the agrin receptor on CNS neurons. Our results show that both agrin and its receptor are concentrated at neuron–neuron synapses. These data support the hypothesis that agrin plays a role in formation and/or function of CNS synapses
Autoantibodies to Agrin in Myasthenia Gravis Patients
To determine if patients with myasthenia gravis (MG) have antibodies to agrin, a proteoglycan released by motor neurons and is critical for neuromuscular junction (NMJ) formation, we collected serum samples from 93 patients with MG with known status of antibodies to acetylcholine receptor (AChR), muscle specific kinase (MuSK) and lipoprotein-related 4 (LRP4) and samples from control subjects (healthy individuals and individuals with other diseases). Sera were assayed for antibodies to agrin. We found antibodies to agrin in 7 serum samples of MG patients. None of the 25 healthy controls and none of the 55 control neurological patients had agrin antibodies. Two of the four triple negative MG patients (i.e., no detectable AChR, MuSK or LRP4 antibodies, AChR-/MuSK-/LRP4-) had antibodies against agrin. In addition, agrin antibodies were detected in 5 out of 83 AChR+/MuSK-/LRP4- patients but were not found in the 6 patients with MuSK antibodies (AChR-/MuSK+/LRP4-). Sera from MG patients with agrin antibodies were able to recognize recombinant agrin in conditioned media and in transfected HEK293 cells. These sera also inhibited the agrin-induced MuSK phosphorylation and AChR clustering in muscle cells. Together, these observations indicate that agrin is another autoantigen in patients with MG and agrin autoantibodies may be pathogenic through inhibition of agrin/LRP4/MuSK signaling at the NMJ
Review: Dystroglycan in the Nervous System
Dystroglycan is part of a large complex of proteins, the dystrophin-glycoprotein complex, which has been implicated in the pathogenesis of muscular dystrophies for a long time. Besides muscular degeneration many patients manifest symptoms of neurological and cognitive dysfunction. Newer findings suggest that dystroglycan is implicated in brain development, synapse formation and plasticity, nerve-glia interactions and maintenance of the blood-brain barrier.
Most research so far has focused on the functions of dystroglycan in muscle and neuromuscular junctions, while its role in the brain and interneuronal synapses has been largely neglected. 
This review will give an overview of the biochemistry of dystroglycan, its interaction with other proteins as well as its confirmed and hypothetical functions in the nervous system in health and diesease
Muscular dystrophy meets protein biochemistry, the mother of invention
Muscular dystrophies result from a defect in the linkage between the muscle fiber cytoskeleton and the basement membrane (BM). Congenital muscular dystrophy type MDC1A is caused by mutations in laminin α2 that either reduce its expression or impair its ability to polymerize within the muscle fiber BM. Defects in this BM lead to muscle fiber damage from the force of contraction. In this issue of the JCI, McKee and colleagues use a laminin polymerization–competent, designer chimeric BM protein in vivo to restore function of a polymerization-defective laminin, leading to normalized muscle structure and strength in a mouse model of MDC1A. Delivery of such a protein to patients could ameliorate many aspects of their disease
- …